Novartis | NVS - Passivo Circulante





Passivo Circulante Alterar Data
AbbVie USD 42.1B 1.19B 2026-03
Amgen USD 24.96B 534M 2026-03
AstraZeneca USD 32.57B 1.95B 2026-03
Bausch Health Companies USD 4.53B 350M 2026-03
Biogen USD 3B 350.5M 2026-03
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Canopy Growth CAD 158.44M 60.15M 2026-03
Corcept Therapeutics USD 149.18M 16.9M 2026-03
Drreddys Laboratories INR 167.57B 165.8B 2026-03
Eli Lilly USD 36.63B 1.41B 2026-03
Gilead Sciences USD 9.48B 2.34B 2026-03
GlaxoSmithKline GBP 22.43B 1.04B 2026-03
Glaxosmithkline GBP 22.43B 6.39B 2026-03
J&J USD 57.72B 3.59B 2026-03
Merck USD 26.94B 1.38B 2026-03
Novartis USD 31.37B 4.1B 2026-03
Novartis USD 31.37B 4.1B 2026-03
Pacira USD 108.79M 11.8M 2026-03
Perrigo USD 997.6M 15.3M 2026-03
Pfizer USD 34.35B 2.64B 2026-03
Phibro Animal Health USD 281.87M 500K 2026-03
Prestige Brands USD 120.92M 18.63M 2026-03
Roche Holding CHF 28B 421M 2025-12
Sanofi EUR 30.01B 1.66B 2026-03
Sanofi EUR 30.01B 1.66B 2026-03
Supernus Pharmaceuticals USD 373.93M 35.76M 2026-03
Zoetis USD 2.05B 182M 2026-03